AIA Group Ltd Grows Position in BeiGene, Ltd. (NASDAQ:BGNE)

AIA Group Ltd lifted its stake in shares of BeiGene, Ltd. (NASDAQ:BGNE) by 38.9% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 18,497 shares of the company’s stock after buying an additional 5,181 shares during the quarter. AIA Group Ltd’s holdings in BeiGene were worth $2,893,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. NewEdge Wealth LLC boosted its position in BeiGene by 7.5% during the 4th quarter. NewEdge Wealth LLC now owns 1,612 shares of the company’s stock valued at $291,000 after purchasing an additional 112 shares during the period. Vestmark Advisory Solutions Inc. raised its stake in BeiGene by 9.5% during the 4th quarter. Vestmark Advisory Solutions Inc. now owns 1,601 shares of the company’s stock valued at $289,000 after acquiring an additional 139 shares in the last quarter. Parkwood LLC raised its stake in BeiGene by 3.0% during the 4th quarter. Parkwood LLC now owns 6,464 shares of the company’s stock valued at $1,166,000 after acquiring an additional 191 shares in the last quarter. Benjamin F. Edwards & Company Inc. raised its stake in BeiGene by 51.5% during the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 821 shares of the company’s stock valued at $128,000 after acquiring an additional 279 shares in the last quarter. Finally, Sectoral Asset Management Inc. raised its stake in BeiGene by 12.6% during the 4th quarter. Sectoral Asset Management Inc. now owns 3,752 shares of the company’s stock valued at $677,000 after acquiring an additional 420 shares in the last quarter. Institutional investors and hedge funds own 48.55% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. JPMorgan Chase & Co. lifted their target price on BeiGene from $184.00 to $186.00 and gave the stock an “overweight” rating in a report on Tuesday, March 19th. Sanford C. Bernstein reduced their price target on BeiGene from $196.00 to $161.00 and set a “market perform” rating for the company in a research report on Wednesday, March 27th. TD Cowen boosted their price objective on BeiGene from $236.00 to $254.00 and gave the stock a “buy” rating in a research report on Thursday, May 9th. Finally, Bank of America cut their price objective on BeiGene from $180.00 to $152.50 and set a “neutral” rating for the company in a research report on Tuesday. Three investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $250.75.

Insider Transactions at BeiGene

In other news, CEO John Oyler sold 2,789 shares of the business’s stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $159.58, for a total transaction of $445,068.62. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, COO Xiaobin Wu sold 1,459 shares of the firm’s stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $159.79, for a total value of $233,133.61. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO John Oyler sold 2,789 shares of BeiGene stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $159.58, for a total value of $445,068.62. The disclosure for this sale can be found here. Insiders sold 6,683 shares of company stock valued at $1,056,089 in the last quarter. 7.43% of the stock is currently owned by corporate insiders.

BeiGene Trading Up 1.1 %

Shares of BeiGene stock traded up $1.67 during trading on Friday, reaching $152.17. 378,036 shares of the stock were exchanged, compared to its average volume of 234,893. The company has a quick ratio of 1.84, a current ratio of 2.08 and a debt-to-equity ratio of 0.06. BeiGene, Ltd. has a 1 year low of $126.97 and a 1 year high of $225.23. The stock’s fifty day moving average is $156.17 and its 200 day moving average is $157.52. The firm has a market cap of $14.75 billion, a price-to-earnings ratio of -20.10 and a beta of 0.59.

BeiGene (NASDAQ:BGNE) last announced its quarterly earnings results on Wednesday, May 8th. The company reported ($2.41) earnings per share for the quarter, beating the consensus estimate of ($3.07) by $0.66. BeiGene had a negative net margin of 28.39% and a negative return on equity of 21.70%. The company had revenue of $751.70 million during the quarter, compared to the consensus estimate of $670.09 million. During the same quarter last year, the firm earned ($3.34) earnings per share. The firm’s quarterly revenue was up 67.9% compared to the same quarter last year. As a group, equities research analysts expect that BeiGene, Ltd. will post -8.24 earnings per share for the current fiscal year.

BeiGene Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.